In last trading session, Kymera Therapeutics Inc (NASDAQ:KYMR) saw 0.53 million shares changing hands with its beta currently measuring 2.31. Company’s recent per share price level of $37.40 trading at $1.1 or 3.03% at ring of the bell on the day assigns it a market valuation of $2.29B. That closing price of KYMR’s stock is at a discount of -21.15% from its 52-week high price of $45.31 and is indicating a premium of 74.33% from its 52-week low price of $9.60. Taking a look at company’s average trading volume volume of 640.03K if we extend that period to 3-months.
Kymera Therapeutics Inc (NASDAQ:KYMR) trade information
Upright in the green during last session for gaining 3.03%, in the last five days KYMR remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $37.40 price level, adding 2.12% to its value on the day. Kymera Therapeutics Inc’s shares saw a change of 46.90% in year-to-date performance and have moved 12.08% in past 5-day. Kymera Therapeutics Inc (NASDAQ:KYMR) showed a performance of 3.20% in past 30-days.
Kymera Therapeutics Inc (KYMR) estimates and forecasts
Statistics highlight that Kymera Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 223.81% of value to its shares in past 6 months, showing an annual growth rate of -25.00% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -31.80% from the last financial year’s standing.
15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.88M for the same. And 13 analysts are in estimates of company making revenue of 9.44M in the next quarter. Company posted 14.06M and 4.73M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -39.18% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -12.54% while estimates for its earnings growth in next 5 years are of 1.90%.
KYMR Dividends
Kymera Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
